Healthy
Conditions
Keywords
Glucocorticoid receptor; antagonist
Brief summary
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral doses of CORT125134 in healthy participants.
Detailed description
This is a 3-part, single-center study of single and multiple ascending doses of CORT125134 in healthy participants. Part I is a single dose study. Initially, participants will be enrolled sequentially into 1 of up to 6 cohorts, each containing 10 participants, in a double-blind, randomized, placebo-controlled assessment of single-ascending doses (SAD) of CORT125134. Within each cohort, 8 participants will be randomly assigned to receive a single dose of CORT125134, and 2 participants will be randomly assigned to receive a single dose of matching placebo. Thereafter, Cohort 7 will be a food-effect cohort, in which all 8 participants will receive a single dose of CORT125134 after a high-fat breakfast (open label). Cohorts 8 and 9 will be pharmacological effect cohorts, in each of which 10 participants will receive a challenge agent (prednisone, 25 mg) alone on Day -19; with an active comparator (mifepristone, 600 mg) on Day -12, and with CORT125134 on Day 1 in an open-label single sequence crossover design. Pharmacological effects will be explored by measuring effects on peripheral blood eosinophil, lymphocyte and neutrophil counts, serum osteocalcin, assay of messenger ribonucleic acid (mRNA) expression of FK506 Binding Protein 5 (FKBP5) and Glucocorticoid-induced Leucine Zipper (GILZ) in whole blood (proof of pharmacological effect Cohort 8) and by measuring effects on oral glucose tolerance (proof of concept Cohort 9). Part 2 and 3 will be double-blind, randomized, placebo-controlled assessments of multiple oral ascending doses (MAD) of CORT125134. Participants will be enrolled sequentially into 1 of up to 4 cohorts (Cohorts 10-13), each containing 12 participants. Within each cohort, 9 participants will be randomly assigned to receive CORT125134 and 3 participants to receive matching placebo daily for 14 days (Days 1-14). The effects of CORT125134 on response to prednisone challenge will be additionally explored in Cohorts 12 and 13 in a single sequence crossover, with prednisone being given alone on Day -5 and in combination with CORT125134 or placebo on Day 14. Throughout the study, routine safety tests and assessments of PK (CORT125134 and CORT125201) will be performed, and changes in serum cortisol and plasma adrenocorticotrophic hormone (ACTH) measured.
Interventions
DRUGCORT125134
Oral capsules
DRUGMatching Placebo of CORT125134
Placebo
DRUGMifepristone
Active comparator
DRUGPrednisone
Challenge agent
DRUGGlucose
Sponsors
Corcept Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Provide written informed consent * Weight \<= 102 kilogram (kg); body mass index (BMI) 18-30 kg/meter squared * Morning serum cortisol in reference range * Willing and able to communicate, participate in the whole study and to abide by study restrictions including use of contraception
Exclusion criteria
* Participation in any clinical research study, received treatment with any investigational drug or device, or donated blood within the previous 3 months * Has a history of alcoholism, substance abuse, or drug abuse within 1 year; positive screen for alcohol or drugs of abuse * Current smokers, smoked and/or used tobacco and/or nicotine-containing products within 6 months, or positive screen for carbon monoxide * Females of childbearing potential, pregnant or breastfeeding, and/or with a positive pregnancy test * Has a condition that could be aggravated by glucocorticoid blockade or activation * Has clinically relevant abnormal findings on vital signs, physical examination, laboratory screening tests, or 12-lead electrocardiogram (ECG) * Has history of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, chronic respiratory, gastrointestinal or neurological disease * Has used systemic glucocorticoids within 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Treatment-Emergent Adverse Events (AEs) (Safety and Tolerability) of CORT125134 | Single dose Cohorts 1-9 Day 1 to Day 15; MAD Cohorts 10-13 Day 1 to Day 28/Day 24 (Cohort 13) |
Secondary
| Measure | Time frame |
|---|---|
| CORT125134 Pharmacokinetic (PK) of total lag time (Tlag) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125134 PK of peak plasma concentration (Cmax) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125134 PK of time to reach maximum observed concentration (Tmax) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts 10-12 Day 1 to Day 28/24 (Cohort 13) |
| CORT125134 PK of area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125201 PK of peak plasma concentration (Cmax) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125201 PK time Lag (Tlag) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125201 PK of time to reach maximum observed concentration (Tmax) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Day 28/24 (Cohort 13) |
| CORT125201 PK of area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) | Single dose Cohorts Day 1 to Day 15; MAD Cohorts Day 1 to Say 28/24 (Cohort 13) |
| QT internal corrected for heart rate using Fridericia's formula (QTcF) exposure-response analysis | SAD Cohorts 1-6: Pre dose through 24 hours post dose; MAD Cohorts: Pre first dose through 24 hours post final dose of Investigational Medicinal Product (IMP) |
| Lymphocyte count | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
| Neutrophil count | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
| Osteocalcin | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
| FKBP5 expression | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
| Glucocorticoid-induced leucine zipper (GILZ) expression | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
| Glucose tolerance | Single dose Cohort 9 Days -19 to Day 2; MAD Cohort 13 Days -5 to Day 15 |
| Serum cortisol | SAD Cohorts 1-6: Pre dose to Day 15; MAD Cohorts 10-11: Pre dose to Day 28 |
| Plasma adrenocorticotrophic hormone (ACTH) | SAD Cohorts 1-6: Pre dose to Day 15; MAD Cohorts 10-11: Pre dose to Day 28 |
| Eosinophil count | Single dose Cohort 8 Days -19 to Day 2; MAD Cohorts 12 and 13 Days -5 to Day 15 |
Countries
United Kingdom
Outcome results
None listed